Investigators from Boston University School of Medicine (BUSM) and the VA Boston Healthcare System have shown, at 6 months in a small group of patients, that there is no difference in efficacy between Bevacizumab (Avastin) and Ranibizumab (Lucentis) for the treatment of age-related macular degeneration (AMD). The study, which appears currently on-line in the American Journal of Ophthalmology , is the first to report early outcomes of a prospective, double-masked, randomized, controlled trial co
More here:
Cancer drug is no different in effectiveness as gold standard treatment for macular degeneration
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
You must log in to post a comment.